Adaptive Clinical Trial of Adenosine A2a Antagonist in Cocaine Dependence

$2P50FY2010DANIH

University Of Texas Hlth Sci Ctr Houston, Houston TX

Investigators

Linked publications & trials

Paper 37344702 Paper 36971714 Paper 36614248 Paper 34994673 Paper 34923324 Paper 34600245 Paper 33119414 Paper 33021143 Paper 32593950 Paper 32267062 Paper 31958903 Paper 31927220 Paper 31631955 Paper 31176066 Paper 30968959 Paper 30625144 Paper 30472571 Paper 30418104 Paper 30408130 Paper 29771557 Paper 29287668 Paper 28498501 Paper 28192722 Paper 27862692 Paper 27646197 Paper 27022201 Paper 27014100 Paper 26693170 Paper 26681735 Paper 26566718 Paper 26512421 Paper 26484829 Paper 26241153 Paper 26170765 Paper 26164486 Paper 26110342 Paper 26082893 Paper 25841982 Paper 25662909 Paper 25414797 Paper 25336321 Paper 25299617 Paper 25134057 Paper 24809448 Paper 24621090 Paper 24618688 Paper 24582546 Paper 24512640 Paper 24507117 Paper 24424425 Paper 24029622 Paper 24026715 Paper 23761390 Paper 23588313 Paper 23549451 Paper 23371492 Paper 23151990 Paper 22969732 Paper 22905331 Paper 22654774 Paper 22464943 Paper 22425411 Paper 22047976 Paper 21730016 Paper 21692148 Paper 21204739 Paper 21172570 Paper 20661285 Paper 20570057 Paper 20545388 Paper 20478631 Paper 20155594 Paper 20153142 Paper 19595517 Paper 19462304 Paper 19353809 Paper 19322730 Paper 19217266 Paper 19058926 Paper 18164144 Paper 18093749 Paper 17994474 Paper 17613964 Paper 17543472 Paper 17321725 Paper 17134849 Paper 16966192 Paper 16839698 Paper 16822120 Paper 16755537 Paper 16713126 Paper 15370932 Paper 15345275 Paper 15039761 Paper 14732428 Paper 11853135 Paper 11593078 Paper 11418225 Paper 11316375 Paper 10940546

Abstract

Chronic cocaine use may produce disruption of monoamine systems (including dopamine). This may in turn contribute to measurable dysfunction in important cognitive and behavioral processes. Pharmacotherapy with stimulants that enhance dopamine (DA) function has shown efficacy in treating cocaine dependence and improving behavioral function ~ supporting the notion that these processes are related. In the development of novel pharmacotherapies for cocaine dependence, an important step is a full understanding of the.psychopharmacological properties of potential medications for cocaine dependence, including subjective, physiological, discriminative and behavioral effects. Selective adenosine (A2A) receptor antagonists may play a key role in the modulation of DA neurotransmission by indirectly enhancing DA receptor activation. Additionally, A2A antagonists inhibit cannabinoid CBI receptor activation, suggesting a potential mechanism for reducing concurrent marijuana use in cocaine dependent patients. A2A antagonists may provide additional benefit on concurrent marijuana use in cocaine dependence, as dual cocaine-marijuana users present unique treatment challenges. This project proposes to evaluate the novel A2A antagonist SYN 115. Its stimulant-like effects may help with affective and behavioral deficiencies related to (a) DA depletion and (b) DA-CB1 interactions. Accordingly, the project aims to characterize the psychopharmacology of SYN115 in individuals with cocaine dependence, cocaine dependence with concurrent marijuana use, and controls. Employing both acute and chronic dosing designs, three experiments will be conducted using well-established psychopharmacological methods in order to characterize dose-response relationships. A mixed-model strategy will be utilized to (a) leverage the power of within-subject, repeated measures designs, and (b) compare cocaine dependent and healthy matched-control subjects. Measures will include drug discrimination, subjective effects, cardiovascular effects, behavioral inhibition (impulsivity), working memory, reversal learning, and decision making. These data will compliment and provide valuable information to our parallel clinical trials using these agents to treat cocaine dependence

View original record on NIH RePORTER →